develop cancer treatment

FRANKFURT: BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb (NYSE: BMY) announced Monday a global collaboration to co-develop and co-commercialize BioNTech’s experimental bispecific antibody, BNT327, for treating solid tumors. The partnership aims to accelerate the development of BNT327, which targets PD-L1 and VEGF-A, two…